← FDA DRUG APPROVALS

FDA ANDA · ANDA076931

BUPRENORPHINE HYDROCHLORIDE

Sponsor: HIKMA

APPLICATION
ANDA076931
TYPE
ANDA
ORIGINAL APPROVAL
2005-03-02
LATEST ACTION
2025-12-22
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

BUPRENORPHINE HYDROCHLORIDEPrescription
BUPRENORPHINE HYDROCHLORIDE EQ 0.3MG BASE/ML · INJECTABLE · INJECTION

Approval history

2025-12-22Labeling · Supplement 16 · standardAP
2020-06-15Labeling · Supplement 12 · standardAP
2019-07-12Manufacturing (CMC) · Supplement 11 · unknownAP
2005-03-02OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →